Karo Pharma AB (publ)

Karo Pharma AB (publ)

KARBF

$5.25

Updated: 22/09/2026, 22:44:39

Market Cap
$1.52B
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Country
SE

No historical data available

Company Profile

Headquartered in Stockholm, Sweden, Karo Pharma AB (publ) specializes in the development and commercialization of both prescription pharmaceuticals and over-the-counter (OTC) health products. These offerings reach pharmacies and retail sectors across numerous global markets, including its home country of Sweden, the Nordic region (Norway, Denmark, Finland), major European economies (France, Germany, Italy), the wider European continent, the United States, and approximately 90 other countries worldwide. The European and Nordic markets represent a particularly strong focus for the company. Karo Pharma boasts a diverse portfolio spanning several health categories. For skin health, prominent brands include Remescar, Locobase, Decubal, and indy beauty. Its intimate health segment features Pevaryl, Multi Gyn, Asan, and Selexid, while foot care is addressed through brands such as Pevaryl, CCS, Nailner, and wortie. The company also provides relief for pain, coughs, and colds under brand names like Paracet, Ibux, Mollipect, and Viruseptin. Essential prescription drugs are marketed under the Burinex, Centyl, Kaleorid, and Lithionit labels. Furthermore, a range of wellness products is available through brands including nutravita, Alpha Foods, Flux, Allévo, Dosett, Dax, and Lactocare. Distribution of these products is managed through various channels, encompassing direct sales organizations, extensive networks of distributors, and online platforms. The company, initially incorporated in 1987, was formerly named Karo Bio AB (publ) before officially rebranding to Karo Pharma AB (publ) in March 2016.

USD
OTC
CEO: Christoffer Lorenzen
Employees: 225
https://www.karohealthcare.com
Asset Summaries
Latest generated summaries for KARBF

No summaries found.

Detailed business
Structured knowledge from the latest official annual filing.
No official annual filing has completed ingestion for this company yet. The filing worker processes major-index companies incrementally and never repeats a completed fiscal year.
Full company information
Latest profile, trading, valuation, and identifier data stored for KARBF.
Share price
$5.25
Market cap
$1.52B
Exchange
OTC
Currency
USD
CEO
Christoffer Lorenzen
Employees
225
IPO date
30/04/2013
Beta
0
Last dividend
$0.00
Day range
$5.25 – $5.25
52-week range
$5.25 – $5.71
1-day performance
0.00%
1-year performance
0.00%
Current drawdown (1Y)
-8.04%
CIK
N/A
CUSIP
N/A
ISIN
N/A
Created
07/12/2025, 04:56:00
Last update
22/09/2026, 22:44:39

Track Karo Pharma AB (publ) with an AI analyst

See which prediction-market events move KARBF, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.

Free forever to follow AlphaBrain’s AI strategies. No card required.

Latest Database News
News linked to KARBF from your Railway `news_articles` table.

No news found for this symbol.